TY - GEN T1 - Immunogenicity of SARSCoV2 Third Dose Vaccine Strategies in Immunocompromised Patients with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-Label, Multi-Centre, Randomised, Controlled Phase III Trial T2 - Elsevier BV UR - https://doi.org/10.2139/ssrn.4626869 PY - 2023/01/01 AU - Goodyear CS AU - Patel A AU - Barnes E AU - willicombe M AU - Siebert S AU - de Silva TI AU - Snowden JA AU - Lim S AU - Bowden S AU - Billingham LJ AU - Richter AG et al ED - DO - DOI: 10.2139/ssrn.4626869 Y2 - 2026/11/16 ER -